Is Retatrutide legal in the US?

Investigational is not a gray zone — it is a hard line

Unlike the seven peptides the FDA’s advisory committee reviewed in July, retatrutide is not a compounding question at all. It is a new molecule owned by Eli Lilly and still inside the approval process. That has three consequences. It has no FDA approval, and no other regulator has approved it either. It is not eligible for pharmacy compounding under section 503A: it is not on the bulks list, it has no USP monograph, and it is not a component of an approved drug — the three routes to eligibility. And Lilly’s own guidance is blunt: the company says no one should take anything claiming to be retatrutide outside a Lilly trial. This page does not provide sourcing, dosing, or preparation guidance.

Where the approval process stands

Lilly announced positive Phase 3 results in May 2026 (TRIUMPH-1, obesity without diabetes) and July 2026 (TRIUMPH-2, obesity with type 2 diabetes; TRIUMPH-3, severe obesity with established cardiovascular disease). In TRIUMPH-3, participants lost up to an average of 22.6% of body weight at 80 weeks. The most common side effects were gastrointestinal — diarrhea, nausea, constipation — consistent with the GLP-1 class. Lilly had earlier signalled a submission as early as 2026; in July it moved the target to the first quarter of 2027, citing the time needed to assemble manufacturing and quality-control data. A standard FDA review then runs roughly ten months, which puts any approval decision at late 2027 at the earliest. Details are on our FDA approval status page.

The one lawful route before approval: expanded access

On August 3, 2026, Lilly confirmed a pre-approval expanded-access program for patients who meet defined clinical criteria and cannot enroll in a trial. It followed weeks of physician pressure after a single compassionate-use case — a 79-year-old patient granted access in April — became public. The program is physician-initiated: a treating clinician applies on the patient’s behalf. Reported criteria include a documented burden of weight-related complications and either failure on maximum-dose standard therapy or a documented discussion of standard options; accounts of the exact criteria vary by outlet, and Lilly says it is reviewing requests from health-care providers. The program is registered on ClinicalTrials.gov as NCT07629401 (status: Available); Lilly’s own explainer is here. Expect it to stay narrow relative to demand.

What is actually being sold as “retatrutide”

Because Lilly’s material reaches patients only through trials and the expanded-access program, any vial sold online, by a clinic, or through a group chat as “retatrutide” is not Lilly’s drug. It is gray-market synthesis of unverified identity, marketed “for research use only”, with no guarantee of purity, dose, or sterility. ECRI and ISMP reported in April 2026 that analytic testing of gray-market peptide products found purity ranging from 5% to 75% of label, with arsenic and lead above the thresholds accepted for injectables; the white paper does not say who performed the testing. Nor is there a compounding workaround: the FDA has since February 2026 been tightening the ingredients and marketing permitted for compounded GLP-1 products, and retatrutide never qualified in the first place.

Primary sources: Eli Lilly, “What to know about retatrutide” (updated July 2026) · ClinicalTrials.gov NCT07629401, pre-approval expanded access (status: Available, verified Aug 2026) · Lilly TRIUMPH-1/2/3 topline announcements (May and July 2026) · trade-press reporting on the Q1 2027 filing target and the expanded-access program (CNBC, BioPharma Dive, AJMC, July–August 2026).